Hello! Welcome to visit Readline 中文版 TEL:+86 0755-2665 9310

Contact Us

  • Contact:Jessie Huang +86 0755-2665 9310
  • Email:sales@szreadline.com
  • Address:2-101,Bio-incubator, Gaoxin C.1st Ave.,Shenzhen Hi-tech Industrial Park,ShenZhen

Novo Nordisk GLP-1 receptor agonist Victoza (liraglutide) has been successfully.

时间:2019-04-30 09:52:55 阅读数:0

Novo Nordisk recently released data on the ELLipsE phase III clinical study of Victoza (liraglutide) at the PES/PAS annual meeting in Baltimore. This is the first phase III study completed in the past 10 years among children and adolescents with type 2 diabetes (10-17 years old) to assess the efficacy and safety of Victoza (1.8 mg) versus placebos. The data confirm Victoza's superiority over placebos in lowering blood sugar.

Novo Nordisk